Published in Biomed Res Int on March 13, 2014
Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.86
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci (2016) 0.84
Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci (2015) 0.84
MicroRNAs in Nonalcoholic Fatty Liver Disease. J Clin Med (2015) 0.82
MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH. J Clin Med (2015) 0.81
MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer (2016) 0.81
Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol (2015) 0.81
Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device. PLoS One (2016) 0.79
Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol (2015) 0.79
Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs. PLoS One (2016) 0.78
Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci (2016) 0.78
Circulating miRNAs: Potential Novel Biomarkers for Hepatopathology Progression and Diagnosis of Schistosomiasis Japonica in Two Murine Models. PLoS Negl Trop Dis (2015) 0.78
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Sci Rep (2016) 0.78
Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison. Sci Rep (2016) 0.77
miRiaD: A Text Mining Tool for Detecting Associations of microRNAs with Diseases. J Biomed Semantics (2016) 0.77
Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep (2016) 0.75
A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men. PLoS One (2016) 0.75
MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737. World J Gastroenterol (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Genomics of microRNA. Trends Genet (2006) 7.75
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37
An analysis of human microRNA and disease associations. PLoS One (2008) 5.21
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (2010) 4.72
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol (2007) 4.40
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature (2011) 4.34
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem (2006) 4.15
MicroRNAs in development and disease. Physiol Rev (2011) 4.13
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet (2007) 3.63
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A (2011) 3.35
Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog (2011) 2.53
Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev (2010) 2.51
Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One (2011) 2.48
MicroRNAs and epigenetics. FEBS J (2011) 2.44
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med (2008) 2.39
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol (2009) 2.03
Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver (1999) 2.01
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology (2008) 1.82
The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One (2011) 1.81
MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One (2009) 1.81
MicroRNAs in lipid metabolism. Curr Opin Lipidol (2011) 1.79
Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol (2012) 1.72
Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis (2012) 1.65
Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol (2009) 1.64
The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One (2010) 1.63
A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem (2010) 1.61
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest (2010) 1.60
Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle (2012) 1.60
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol (2012) 1.59
Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest (2010) 1.59
MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res (2010) 1.56
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun (2011) 1.52
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
microRNAs and cholesterol metabolism. Trends Endocrinol Metab (2010) 1.49
Steatosis as a risk factor in liver surgery. Ann Surg (2007) 1.48
Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology (2009) 1.45
Emerging role of microRNAs in liver diseases. World J Gastroenterol (2009) 1.45
Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res (2009) 1.43
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun (2011) 1.41
MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut (2012) 1.40
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One (2011) 1.39
Hepatocellualar carcinoma serum markers. Semin Oncol (2012) 1.39
Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med (2012) 1.35
Genomic organization of microRNAs. J Cell Physiol (2010) 1.35
Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer (2010) 1.34
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2010) 1.31
MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene (2011) 1.31
The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr (2011) 1.30
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 1.30
Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.27
MicroRNAs: new players in cardiac injury and protection. Mol Pharmacol (2011) 1.26
PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology (2007) 1.26
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther (2009) 1.23
Epidemiology and natural history of patients with NAFLD. Curr Pharm Des (2013) 1.21
Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta (2013) 1.21
MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis (2008) 1.21
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol (2009) 1.17
MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr Opin Lipidol (2012) 1.17
Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer (2011) 1.16
Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci (2011) 1.16
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16
MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumour Biol (2012) 1.15
Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol Metab (2012) 1.15
Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci (2008) 1.15
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Computational challenges in miRNA target predictions: to be or not to be a true target? J Biomed Biotechnol (2009) 1.14
Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome. Hepatology (2013) 1.13
Nonalcoholic fatty liver disease. Prog Liver Dis (1986) 1.11